Abstract 4872
Background
Cancer patients with HVB, HCV and HIV receiving systemic therapy are at risk of reactivation. It is relevant to determine the serologic status of patients at high risk. The CDC has broad screening recommendations for HBV, HCV and HIV. ASCO recommends HBV screening in patients with risk factors, before starting anti-CD20 therapy or stem-cell transplantation. In this population-based study we determine the rates of screening in a large cohort of elderly patients with solid tumors.
Methods
Patients with solid tumors (>66 yo) diagnosed between 2007-2013 and treated with systemic anticancer therapy were identified in the SEER-Medicare database. HBV, HCV and HIV testing was identified using HCPCS codes, the screening period was defined as testing within the first year of cancer diagnosis and no later than 30 days after the first dose of systemic anticancer therapy. Descriptive statistics and logistic regression were used.
Results
A total of 70,488 patients were included. The rates of HBV, HCV and HIV screening were 4.13%, 2.05% and 0.73%, respectively. The median time from cancer diagnosis to screening were 26, 24 and 22 days for HBV, HCV and HIV respectively. Screening rates varied according to cancer type. The highest HBV screening rates were in pancreas (18.9%), melanoma (4.7%) and prostate cancer (5.7%). For HCV, melanoma (7.6%), prostate (3.6%) and anal/penile/vagina/vulvar cancers (2.9%). For HIV, the highest rates were in patients with anal/penile/vagina/vulvar cancers (6.7%), melanoma (2.7%), cervix/endometrial cancers (1.5%). Screening rates increased over time, in addition, males, younger patients and those living in urban areas had higher screening rates (all p < 0.001). Asians had the highest screening rates of HBV and HCV while African Americans had the highest HIV screening rate.
Conclusions
HBV, HCV and HIV screening rates were very low among elderly cancer patients receiving systemic anticancer therapy. There was significant variability in the screening rates according to cancer site and patient characteristics. Guidance is needed to select patients that can benefit from screening in order to avoid potential complications.
Clinical trial identification
Legal entity responsible for the study
Mariana Chavez MacGregor.
Funding
CIPRIT.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract